NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read Moreby Selina McKee | Sep 9, 2020 | News | 0
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read Moreby Anna Smith | Aug 29, 2019 | News | 0
The transaction is expected to close by the end of 2019.
Read Moreby Anna Smith | Apr 16, 2019 | News | 0
The decision was won by a majority of more than 75%.
Read Moreby Anna Smith | Mar 27, 2019 | News | 0
A filing for ozanimod was initially rejected by the US regulator in February 2017.
Read Moreby Anna Smith | Mar 22, 2019 | News | 0
Exscientia has announced a three-year drug discovery AI collaboration with Celgene.
Read Moreby Anna Smith | Jan 7, 2019 | News | 0
Bristol-Myers Squibb has unveiled its intent to acquire Celgene in a deal worth $74 billion, in order to “create a premier innovative biopharma company”.
Read Moreby Selina McKee | Sep 21, 2018 | News | 0
Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
Read Moreby Selina McKee | Jul 5, 2018 | News | 0
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Read Moreby Selina McKee | Jul 2, 2018 | News | 0
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Read Moreby Selina McKee | Mar 1, 2018 | News | 0
US regulators are refusing to file Celgene’s application to market its experimental multiple sclerosis therapy ozanimod.
Read Moreby Selina McKee | Dec 15, 2017 | News | 0
Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a five-year drug-discovery deal with Celgene to develop and commercialise new anti-cancer treatments.
Read Moreby Selina McKee | Oct 20, 2017 | News | 0
Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
